Avalyn Pharma
AVLN
25.53
+0.10
+0.39%
Avalyn Pharma
US · AVLN
#3161 by market cap
Listed 2026
25.53
+0.10
+0.39%
Live - 5344 symbols - heartbeat 281s ago
· 2026-10-08 04:12
Pre-market
25.98
+1.74%
After-hours
25.53
0.00%
- Market cap
- 1.13B
- P/E (TTM)i
- -10.96
- P/Bi
- 2.84
- EPSi
- -2.04
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on AVLN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.9 percentage points.
Institutional ownership
- Held by institutions
- 108.86% +2.95pp
- Institutions
- 117 +5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund50.36%
Mutual Fund37.90%
Hedge Fund19.03%
Public Company0.81%
Sovereign Wealth Fund0.62%
Top holders as of 2026-06-30
Novo Holdings A/S
8.76% · 3.88M sh
FMR
8.01% · 3.55M sh
T. Rowe Price Group, Inc.
7.53% · 3.34M sh
SR One Capital Management, LP
7.46% · 3.31M sh
Perceptive Advisors LLC
6.03% · 2.68M sh
Montanova Capital, LLC
5.65% · 2.50M sh
F Prime, Inc.
5.15% · 2.28M sh
Impresa Management LLC
5.15% · 2.28M sh
NVP Associates, LLC
5.12% · 2.27M sh
Wellington Management Group
4.97% · 2.20M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
29 filings tracked · 16 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Wellington Management Group | -- | -- |
| Novo Holdings A/S | -- | -- |
| Douglas Carlson | CFO & Chief Business Officer | -- |
| Heather Turner | Independent Chairperson | -- |
| Lyn Baranowski | Chief Executive Officer | -- |
| Kathryn Haviland | Independent Director | -- |
| Impresa Management LLC | -- | -- |
| Jon Congleton | Independent Director | -- |
| Robert Meyer | Director | -- |
| Erin Lavelle | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Robert Meyer | Director | Other Derivative Acquisition | +31,182 | $34.28 |
| 2026-04-30 | Wellington Management Group | -- | Derivative Exercise and Retained | +1,275,486 | -- |
| 2026-04-30 | Novo Holdings A/S | -- | Private Acquisition | +555,555 | $18.00 |
| 2026-04-30 | Novo Holdings A/S | -- | Derivative Exercise and Retained | +3,327,734 | -- |
| 2026-04-30 | Impresa Management LLC | -- | Derivative Exercise and Retained | +2,284,535 | -- |
| 2026-04-30 | SR One Capital Management, LP | -- | Private Acquisition | +555,555 | $18.00 |
| 2026-04-30 | SR One Capital Management, LP | -- | Derivative Exercise and Retained | +2,753,094 | -- |
| 2026-04-29 | Douglas Carlson | CFO & Chief Business Officer | Other Derivative Acquisition | +211,975 | $18.00 |
| 2026-04-29 | Erin Lavelle | Independent Director | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Novo Holdings A/S | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Douglas Carlson | CFO & Chief Business Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Heather Turner | Independent Chairperson | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Heather Turner | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Lyn Baranowski | Chief Executive Officer | Other Derivative Acquisition | +501,033 | $18.00 |
| 2026-04-28 | Lyn Baranowski | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Kathryn Haviland | Independent Director | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Kathryn Haviland | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Jon Congleton | Independent Director | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Jon Congleton | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Erin Lavelle | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:12:40 · For reference only, not investment advice and not tailored to your situation.